Peptides in Ophthalmology

Overview

The eye is an appealing target for peptide therapeutics. The ocular surface allows topical application without systemic exposure; the anterior chamber and vitreous can receive injected peptides with long local residence; and the retina's layered neural architecture is organized around peptide-rich synaptic networks. Rapid advances in ophthalmic peptides reflect both the unique accessibility of the eye and the growing recognition that many eye diseases involve specific, peptide-druggable pathways.

This article surveys ocular peptide research. See peptides in wound care for shared themes of tissue repair and antimicrobial research for ocular host defense.

Research Directions

Dry Eye Disease

Dry eye is one of the most common reasons for ophthalmology visits. Peptide therapies include:

• Lifitegrast — technically a small-molecule LFA-1/ICAM-1 interaction inhibitor, not a peptide, but inspired by peptide leads.
• Thymosin β4 (Tβ4) — a 44-amino-acid peptide with actin-binding and anti-inflammatory activity; in clinical development for dry eye, neurotrophic keratitis, and corneal wound healing.
• Cenegermin (rhNGF) — recombinant nerve growth factor for neurotrophic keratitis, a classic peptide-protein therapeutic delivered topically.
• RegeneRx's RGN-259 — a Tβ4 eye drop formulation.
• Enkephalin and opioid peptides — studied for their effects on corneal epithelial proliferation.
• Cathelicidin (LL-37) and antimicrobial peptides — candidates for dry eye with a microbial component and for contact lens care.

Retinal and Choroidal Vascular Disease

Neovascular age-related macular degeneration (AMD), diabetic macular edema, and related retinal vascular diseases have been revolutionized by anti-VEGF therapies. These include:

• Aflibercept — a VEGF receptor fusion protein.
• Brolucizumab, ranibizumab, faricimab — antibodies and antibody fragments.
• Peptide VEGF inhibitors — early-stage peptide antagonists of VEGF-VEGFR2 binding.
• Anti-angiogenic peptides from natural sources — endostatin, tumstatin, angiostatin-derived peptides.
• Integrin-targeted peptides (RGD motifs) for retinal neovascularization.

The intravitreal route tolerates peptide and protein drugs well, and long-acting depot formulations (port delivery system, peptide-based hydrogels) are reducing injection frequency.

Glaucoma

Glaucoma is primarily treated with small molecules (prostaglandin analogs, beta blockers, Rho kinase inhibitors). Peptide research in glaucoma focuses on:

• Neuroprotective peptides — erythropoietin-derived peptides, mitochondrial-targeted peptides (SS-31), and TrkB agonist peptides for retinal ganglion cell survival.
• Peptide modulators of aqueous outflow — targeting trabecular meshwork function.

Corneal Wound Healing

The cornea's avascular, transparent architecture demands rapid, high-fidelity healing. Peptides under study include:

• Thymosin β4 — promotes corneal re-epithelialization.
• Substance P and IGF-1 combinations — the so-called "FGLM-NH2" peptide derived from substance P has clinical evidence in neurotrophic keratitis.
• Growth factor peptides and EGF fragments.
• Defensins and antimicrobial peptides protecting against infection during healing.

Ocular Infections and Antimicrobial Peptides

Bacterial keratitis (especially Pseudomonas in contact lens users) and fungal keratitis often resist conventional antibiotics. Antimicrobial peptides — synthetic cathelicidins, melittin derivatives, designed peptides — are active areas of research, including peptide-coated contact lenses. See antimicrobial research.

Uveitis and Ocular Inflammation

Peptide immunomodulators (mimics of regulatory cytokines, αMSH-derived peptides) are being explored for ocular inflammation. α-MSH has long been studied for anti-inflammatory actions at the eye, and is endogenously present in the aqueous humor.

Diabetic Retinopathy

Beyond anti-VEGF biologics, peptide modulators of kallikrein-kinin signaling and peptide VEGF antagonists are under investigation for diabetic retinal disease.

Inherited Retinal Dystrophies

Peptide-conjugated antisense oligonucleotides and peptide-mediated gene delivery are emerging tools for inherited retinopathies including Stargardt disease, retinitis pigmentosa, and Leber congenital amaurosis. See peptide drug conjugates.

Methodological Considerations

Ocular peptide delivery is simplified at the surface but complicated elsewhere:

• Topical eye drops — short residence time; peptide stability on the ocular surface is a concern. See stability challenges.
• Intravitreal injection — long residence in the vitreous but burden of repeat procedures.
• Suprachoroidal and subretinal routes — for targeted retinal delivery.
• Sustained-release implants and hydrogels — extending peptide activity over months.

Ocular pharmacokinetics is its own specialty; species differences (rabbit, non-human primate) matter because corneal thickness, lacrimation, and vitreous volume differ substantially. See animal models.

Diagnostic endpoints include best-corrected visual acuity, OCT imaging of retinal layers, corneal fluorescein staining, and increasingly deep-learning-based image biomarkers.

Clinical Development

Cenegermin demonstrated that peptide-protein therapeutics can succeed in rare ophthalmic indications. Thymosin β4 formulations are advancing. Anti-VEGF treatment remains a massive ongoing clinical enterprise. See clinical trial phases and drug development pipeline.

Safety and Limitations

Ocular peptide therapies face typical concerns:

• Preservative selection for multi-use bottles.
• Ocular surface tolerability — burning, injection, corneal toxicity.
• Intraocular pressure effects of intravitreal agents.
• Immunogenicity for repeat intravitreal administration.

See peptide safety and purity and testing.

Future of the Field

The ophthalmic peptide pipeline includes:

• Long-acting anti-VEGF peptides replacing monthly intravitreal antibody injections.
• Peptide-PROTACs and peptide drug conjugates for retinal disease.
• AI-designed peptides for specific ocular targets — see AI peptide discovery and peptide libraries.
• Peptide neuroprotection for glaucoma and inherited dystrophies.
• Biomaterial-peptide hybrids for corneal regeneration.

See future of peptides for broader context.

Summary

Ophthalmology is a productive field for peptide therapeutics, benefiting from accessible delivery, clear clinical endpoints, and biologically tractable targets. From thymosin β4 for dry eye to anti-VEGF therapies that have preserved vision in millions of patients, ocular peptides exemplify how peptide biology translates into meaningful clinical benefit.